Iron Restriction to Clinical Isolates of Candida albicans by the Novel Chelator DIBI Inhibits Growth and Increases Sensitivity to Azoles In Vitro and In Vivo in a Murine Model of Experimental Vaginitis
Open accessThe DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.
Abstract
Candida albicans is an important opportunistic pathogen causing various human infections that are often treated with azole antifungals. The U.S. CDC now regards developing candidal antifungal resistance as a threat, creating a need for new and more effective antifungal treatments. Iron is an essential nutrient for all living cells, and there is growing evidence that interference with iron homeostasis of C. albicans can improve its response to antifungals. This study was aimed at establishing whether withholding iron by currently used medical iron chelators and the novel chelator DIBI could restrict growth and also enhance the activity of azoles against clinical isolates of C. albicans. DIBI, but not deferoxamine or deferiprone, inhibited the growth of C. albicans at relatively low concentrations in vitro, and this inhibition was reversed by iron addition. DIBI in combination with various azoles demonstrated stronger growth inhibition than the azoles alone and greatly prolonged the inhibition of cell multiplication. In addition, the administration of DIBI along with fluconazole (FLC) to mice inoculated with an FLC-sensitive isolate in a model of experimental C. albicans vaginitis showed a markedly improved clearance of infection. These results suggest that iron chelation by DIBI has the potential to enhance azole efficacy for the treatment of candidiasis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Modulation of iron levels alters C. albicans dissemination, infection severity, membrane ergosterol levels, and host immune response (largely mediated by iron-induced changes in the levels of immunogenic glucans in the cell wall) (22–25).”
From Candida albicans enhances iron uptake to maintain fluconazole resistance (2025) · cites this paper as [23]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Antibiotic resistance threats in the United States, 2019
(U.S.), C. F. D. C. A. P. (2019) · doi:10.15620/cdc:82532 · Cited by 5,782
Epidemiology of Invasive Candidiasis: a Persistent Public Health Problem
Pfaller, M. A., & Diekema, D. J. (2007) · Clinical Microbiology Reviews · doi:10.1128/cmr.00029-06 · Cited by 4,174 · cited 1×
“are commonly associated with health care-associated infections in the United States as well as worldwide (1).”
BackgroundSynergy, antagonism, and what the chequerboard puts between them
Odds, F. C. (2003) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkg301 · Cited by 2,481
Sobel, J. D. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60917-9 · Cited by 1,270
An integrated model of the recognition of Candida albicans by the innate immune system
Netea, M. G., Brown, G. D., Kullberg, B. J., & Gow, N. A. R. (2008) · Nature Reviews Microbiology · doi:10.1038/nrmicro1815 · Cited by 946 · cited 1×
“It is becoming increasingly clear that the innate immune response is an important host defense against Candida infection (13), with iron availability and sequestration being important components of susceptibility and immunity (14–16).”
BackgroundThe Battle for Iron between Bacterial Pathogens and Their Vertebrate Hosts
Skaar, E. P. (2010) · PLoS Pathogens · doi:10.1371/journal.ppat.1000949 · Cited by 796
Iron availability and infection
Weinberg, E. D. (2009) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2008.07.002 · Cited by 516
Pfaller, M. A., & Diekema, D. J. (2012) · Journal of Clinical Microbiology · doi:10.1128/jcm.00937-12 · Cited by 484
Pharmacokinetics of antifungal drugs: practical implications for optimized treatment of patients
Bellmann, R., & Smuszkiewicz, P. (2017) · Infection · doi:10.1007/s15010-017-1042-z · Cited by 389 · cited 1×
“Additionally, FLC administered orally is highly bioavailable rapidly 204 entering the systemic circulation for delivery to tissues including into vaginal secretions but with 205 >60% of the FLC load being eliminated non-metabolized and intact via urinary excretion (41).”
BackgroundEpidemiology of invasive candidiasis
Arendrup, M. C. (2010) · Current Opinion in Critical Care · doi:10.1097/mcc.0b013e32833e84d2 · Cited by 376 · cited 1×
“predisposing host factors are implicated in infection (12).”
BackgroundLiu, T. T., Lee, R. E. B., Barker, K. S., Lee, R. E., Wei, L., Homayouni, R., & Rogers, P. D. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.6.2226-2236.2005 · Cited by 313 · cited 1×
“albicans (47), indicating an increased need for iron in response to azole exposure.”
BackgroundAn Overview of Fungal Infections
Garber, G. (2001) · Drugs · doi:10.2165/00003495-200161001-00001 · Cited by 309 · cited 3×
“While this is rarely life threatening, it can significantly impact a patient’s quality of life (4, 5) and may spread to other individuals or become invasive (4).”
BackgroundShared and distinct mechanisms of iron acquisition by bacterial and fungal pathogens of humans
Caza, M., & Kronstad, J. W. (2013) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2013.00080 · Cited by 306
(1974) · Elsevier eBooks · doi:10.1016/c2013-0-11231-7 · Cited by 248
Hou, Y., Zhang, S., Wang, L., Li, J., Qu, G., He, J., Rong, H., Ji, H., & Liu, S. (2012) · Gene · doi:10.1016/j.gene.2012.09.060 · Cited by 210
Candida albicans drug resistance—Another way to cope with stress
Cannon, R. D., Lamping, E., Holmes, A. R., Niimi, K., Tanabe, K., Niimi, M., & Monk, B. C. (2007) · Microbiology · doi:10.1099/mic.0.2007/010405-0 · Cited by 208 · cited 1×
“(43–45) and correspondingly depletes the ergosterol content of membranes (46).”
BackgroundFluconazole-Resistant Candida albicans Vulvovaginitis
Marchaim, D., Lemanek, L., Bheemreddy, S., Kaye, K. S., & Sobel, J. D. (2012) · Obstetrics & Gynecology · doi:10.1097/aog.0b013e31827307b2 · Cited by 195
Pathogenicity and drug resistance in Candida albicans and other yeast species
Mishra, N., Prasad, T., Sharma, N., Payasi, A., Prasad, R., Gupta, D., & Singh, R. (2007) · Acta Microbiologica et Immunologica Hungarica · doi:10.1556/amicr.54.2007.3.1 · Cited by 168
Martel, C. M., Parker, J. E., Bader, O., Weig, M., Gross, U., Warrilow, A. G. S., Kelly, D. E., & Kelly, S. L. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00303-10 · Cited by 165
Natural resistance, iron and infection: a challenge for clinical medicine
Bullen, J. J., Rogers, H. J., Spalding, P. B., & Ward, C. G. (2006) · Journal of Medical Microbiology · doi:10.1099/jmm.0.46386-0 · Cited by 163 · cited 1×
“Additionally, 70 lactoferrin, a key iron withholding defense protein of vertebrate animals and essential for 71 restricting iron availability to pathogens in vivo (26), has been shown to improve the in vitro 72 efficacies of various antifungal agents, including FLC (27, 28).”
BackgroundEvolution of Drug Resistance in Candida Albicans
Cowen, L. E., Anderson, J. B., & Kohn, L. M. (2002) · Annual Review of Microbiology · doi:10.1146/annurev.micro.56.012302.160907 · Cited by 151 · cited 1×
“With the limited range of available antifungal drug classes (5, 8) 53 and growing incidence of azole resistance (7, 9-11), agents that might enhance or broaden the 54 efficacies of the azole antifungals would be attractive.”
BackgroundPrasad, T., Chandra, A., Mukhopadhyay, C. K., & Prasad, R. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00653-06 · Cited by 149
Kuipers, M. E., de Vries, H. G., Eikelboom, M. C., Meijer, D. K. F., & Swart, P. J. (1999) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.43.11.2635 · Cited by 148 · cited 1×
“Additionally, lactoferrin, a key iron-withholding defense protein of vertebrate animals and essential for restricting iron availability to pathogens in vivo (26), has been shown to improve the in vitro efficacies of various antifungal agents, including fluconazole (FLC) (27, 28).”
BackgroundEstradiol-Treated Female Mice as Surrogate Hosts for Neisseria gonorrhoeae Genital Tract Infections
Jerse, A. E., Wu, H., Packiam, M., Vonck, R. A., Begum, A. A., & Garvin, L. E. (2011) · Frontiers in Microbiology · doi:10.3389/fmicb.2011.00107 · Cited by 140 · cited 1×
“Interestingly, estrogen administration has been shown to increase iron availability in the host (17–19), with a correspondingly increased susceptibility to infection (17, 19).”
BackgroundAntibacterial Activities of Iron Chelators against Common Nosocomial Pathogens
Thompson, M. G., Corey, B. W., Si, Y., Craft, D. W., & Zurawski, D. V. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01197-12 · Cited by 135 · cited 1×
“(33) also demonstrated that deferoxamine was not inhibitory for a”
BackgroundLamb, D. C., Kelly, D. E., White, T. C., & Kelly, S. L. (2000) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.44.1.63-67.2000 · Cited by 133
Bondaryk, M., Kurzątkowski, W., & Staniszewska, M. (2013) · Advances in Dermatology and Allergology · doi:10.5114/pdia.2013.38358 · Cited by 126 · cited 2×
“With the limited range of available antifungal drug classes (5, 8) 53 and growing incidence of azole resistance (7, 9-11), agents that might enhance or broaden the 54 efficacies of the azole antifungals would be attractive.”
BackgroundFiori, A., & Van Dijck, P. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.06017-11 · Cited by 112 · cited 5×
“DIBI and FLC were tested in a checkerboard assay in 96-well plates in a similar manner to that described by Fiori and Van Dijck (32), with the following modifications.”
BackgroundMethodInfluentialOxman, D. A., Chow, J. K., Frendl, G., Hadley, S., Hershkovitz, S., Ireland, P., McDermott, L. A., Tsai, K., Marty, F. M., Kontoyiannis, D. P., et al. (2010) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkq136 · Cited by 105
Candida albicans specializations for iron homeostasis: from commensalism to virulence
Noble, S. M. (2013) · Current Opinion in Microbiology · doi:10.1016/j.mib.2013.09.006 · Cited by 104
Rahman, D., Mistry, M., Thavaraj, S., Challacombe, S., & Naglik, J. R. (2007) · Microbes and Infection · doi:10.1016/j.micinf.2007.01.012 · Cited by 102 · cited 1×
“Estrogen administration is also a requirement to predispose mice to experimental candidal vaginitis (7, 20).”
BackgroundIron-Limited Biofilms of Candida albicans and Their Susceptibility to Amphotericin B
Baillie, G. S., & Douglas, L. J. (1998) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.42.8.2146 · Cited by 96 · cited 1×
“albicans iron-limited biofilms have been shown to be more sensitive to amphotericin B (25).”
BackgroundLambs, L., Révérend, B. D.-L., Kozłowski, H., & Berthon, G. (1988) · Inorganic Chemistry · doi:10.1021/ic00290a022 · Cited by 95
Garvey, E. P., Hoekstra, W. J., Schotzinger, R. J., Sobel, J. D., Lilly, E. A., & Fidel, P. L. (2015) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00185-15 · Cited by 82 · cited 2×
“Estrogen administration is also a requirement to predispose mice to experimental candidal vaginitis (7, 20).”
BackgroundSelf-citationZarember, K. A., Cruz, A. R., Huang, C.-Y., & Gallin, J. I. (2009) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01547-08 · Cited by 78 · cited 1×
“(34) demonstrated the synergy between deferiprone and FIG 4 Long-term growth inhibition of C.”
BackgroundIron Metabolism: A Promising Target for Antibacterial Strategies
Ballouche, M., Cornelis, P., & Baysse, C. (2009) · Recent Patents on Anti-Infective Drug Discovery · doi:10.2174/157489109789318514 · Cited by 76 · cited 1×
“66 Therefore, targeting iron acquisition provides a potential basis for a new approach to 67 antimicrobials (24).”
BackgroundMetal Binding in Tetracyclines. Cobalt(II) and Nickel(II) Complexes1
Baker, W. A., & Brown, P. M. (1966) · Journal of the American Chemical Society · doi:10.1021/ja00958a041 · Cited by 76 · cited 1×
“However, the tetracyclines also bind Co and Ni (37) as well as Ca and Mg (38).”
BackgroundMechanisms of resistance to azole antifungals.
Marichal, P., & Vanden Bossche, H. (1995) · Acta Biochimica Polonica · doi:10.18388/abp.1995_4904 · Cited by 72 · cited 1×
“Binding of the azoles and the 245 subsequent inactivation of this enzyme as their known mode of action prevents demethylation of 246 lanosterol (43-45) and correspondingly depletes the ergosterol content of membranes (46).”
BackgroundShi, W., Chen, Z., Chen, X., Cao, L., Liu, P., & Sun, S. (2010) · FEMS Yeast Research · doi:10.1111/j.1567-1364.2010.00664.x · Cited by 71 · cited 1×
“(35) proposed that minocycline enhances FLC penetration due to Ca efflux, while Fiori and Van Dijck (32) concluded that doxycycline enhancement of FLC was related to its iron-binding activity.”
BackgroundCraven, R. J., Mallory, J. C., & Hand, R. A. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m706770200 · Cited by 67
Mechanisms of antifungal resistance.
BOSSCHE, H. V. (1997) · PubMed · Cited by 54
Kobayashi, T., Kakeya, H., Miyazaki, T., Izumikawa, K., Yanagihara, K., Ohno, H., Yamamoto, Y., Tashiro, T., & Kohno, S. (2011) · Japanese Journal of Infectious Diseases · doi:10.7883/yoken.64.292 · Cited by 48 · cited 1×
“Additionally, 70 lactoferrin, a key iron withholding defense protein of vertebrate animals and essential for 71 restricting iron availability to pathogens in vivo (26), has been shown to improve the in vitro 72 efficacies of various antifungal agents, including FLC (27, 28).”
BackgroundHolbein, B. E., & Mira de Orduña, R. (2010) · FEMS Microbiology Letters · doi:10.1111/j.1574-6968.2010.01956.x · Cited by 36 · cited 1×
“We 183 have shown that DIBI is strongly iron selective and does not bind Ca, Mg, Co or Ni (30), 184 therefore, it is unlikely that sequestration of these other essential metals was related to its 185 observed activity.”
BackgroundSelf-citationA Review of the Ultrastructural Features of Superficial Candidiasis
Jayatilake, J. A. M. S. (2010) · Mycopathologia · doi:10.1007/s11046-010-9373-7 · Cited by 34 · cited 1×
“As Candida typically 46 inhabits the skin and mucosa, Candidiasis is often superficial in nature (3); these infections are 47 incredibly common affecting millions of people worldwide (4).”
BackgroundEfficacy of D0870 treatment of experimental Candida vaginitis
Fidel, P. L., Cutright, J. L., & Sobel, J. D. (1997) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.41.7.1455 · Cited by 22
Self-citationYokoyama, T., Nakano, K., & Zenki, M. (1999) · Analytica Chimica Acta · doi:10.1016/s0003-2670(99)00504-8 · Cited by 10 · cited 1×
“iron specific and can also bind Ni, Cu, Co, and Zn (40).”
BackgroundAbsorption of Tetracyclines: Interference by Iron
Greenberger, N. J. (1971) · Annals of Internal Medicine · doi:10.7326/0003-4819-74-5-792 · Cited by 10 · cited 1×
“bind iron, and this iron interaction can neutralize these agents, interfering with antibiotic uptake (36).”
BackgroundHamad, M. A., & Awadallah, S. M. (2013) · Medical Hypotheses · doi:10.1016/j.mehy.2013.10.019 · Cited by 9 · cited 2×
“Interestingly, estrogen administration has been shown to increase iron availability in the 60 host (17-19) with a correspondingly increased susceptibility to infection (17, 19).”
Background
Research works printed but not linked: 2
- Clinical and Laboratory Standards Institute. 2008. Reference method for broth dilution antifungal susceptibility testing of yeasts; approved standard—3rd ed. CLSI document M27-A3. Clinical and Laboratory Standards Institute, Wayne, PA.
- Clinical and Laboratory Standards Institute. 2012. Reference method for broth dilution antifungal susceptibility testing of yeasts; 4th informational supplement. CLSI document M27-S4. Clinical and Laboratory Standards Institute, Wayne, PA.
Cited by
Fungal Lanosterol 14α-demethylase: A target for next-generation antifungal design
Monk, B. C., Sagatova, A. A., Hosseini, P., Ruma, Y. N., Wilson, R. K., & Keniya, M. V. (2019) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2019.02.008 · Cited by 164
Sheng, M. M., Jia, H. K., Zhang, G. Y., Zeng, L. N., Zhang, T. T., Long, Y. H., Lan, J. Q., Hu, Z. Q., Zeng, Z., Wang, B., et al. (2020) · Journal of Microbiology and Biotechnology · doi:10.4014/jmb.1910.10066 · Cited by 90
Jin, X., Zhang, M., Lu, J., Duan, X., Chen, J., Liu, Y., Chang, W., & Lou, H. (2021) · Journal of Advanced Research · doi:10.1016/j.jare.2021.06.016 · Cited by 75
Iron‐MOFs for Biomedical Applications
Yu, Z., Lepoitevin, M., & Serre, C. (2024) · Advanced Healthcare Materials · doi:10.1002/adhm.202402630 · Cited by 73
Tripathi, A., Liverani, E., Tsygankov, A. Y., & Puri, S. (2020) · Journal of Biological Chemistry · doi:10.1074/jbc.ra120.013413 · Cited by 56
Metadata
- Authors
- Savage, K. A., Parquet, M. D. C., Allan, D. S., Davidson, R. J., Holbein, B. E., Lilly, E. A., & Fidel, P. L.
- Affiliations
- Chelation Partners Inc., Halifax, Nova Scotia, Canada
- Dalhousie University (CA)
- Louisiana State University (US)
- Venue
- Antimicrobial Agents and Chemotherapy
- Publisher
- American Society for Microbiology
- Published
- 2018-08
- Volume
- 62
- Issue
- 8
- ISSN
- 0066-4804 (ISSN-L)
- 1098-6596
- PMC
- PMC6105849
- OpenAlex
- W2807244885
- Cited by
- 53
- References
- 48
- Citations by year
- 2026: 2 · 2025: 7 · 2024: 5 · 2023: 7 · 2022: 7 · 2021: 5 · 2020: 8 · 2019: 9 · 2018: 3
- FWCI
- 4.73
- Type
- journal article
- Language
- en
- Update notices
- correction (2019-01-29)
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- journals.asm.org/non-commercial-tdm-license (tdm)
- Locations
- Antimicrobial Agents and Chemotherapy (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Government of Canada
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Fungal and yeast genetics research
- Life Sciences › Agricultural and Biological Sciences › Plant Science › Fungal Plant Pathogen Control
- Keywords
- Candida albicans, iron chelation, iron limitation, fluconazole, candidiasis, vaginal candidiasis, antifungal resistance, iron homeostasis, deferoxamine, deferiprone, combination antifungal therapy, mouse infection model
- MeSH terms
- Deferiprone, Animals, Antifungal Agents, Azoles, Candida, Candida albicans, Deferoxamine, Disease Models, Animal, Drug Synergism, Female, Vaginitis, Drug Resistance, Fungal, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.